Alnylam Pharmaceuticals Inc (ALNY) - Total Assets
Based on the latest financial reports, Alnylam Pharmaceuticals Inc (ALNY) holds total assets worth $4.97 Billion USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Alnylam Pharmaceuticals Inc stock price for real-time trading data and today's change.
Alnylam Pharmaceuticals Inc - Total Assets Trend (2002–2025)
This chart illustrates how Alnylam Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. Also see Alnylam Pharmaceuticals Inc operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Alnylam Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Alnylam Pharmaceuticals Inc's total assets of $4.97 Billion consist of 81.6% current assets and 18.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 33.4% |
| Accounts Receivable | $777.57 Million | 15.7% |
| Inventory | $82.72 Million | 1.7% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $593.73 Million | 12.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2002–2025)
This chart illustrates how Alnylam Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital to net assets of Alnylam Pharmaceuticals Inc to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Alnylam Pharmaceuticals Inc's current assets represent 81.6% of total assets in 2025, a decrease from 96.3% in 2002.
- Cash Position: Cash and equivalents constituted 33.4% of total assets in 2025, down from 96.1% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 11.0% of total assets, an increase from 0.0% in 2002.
- Asset Diversification: The largest asset category is accounts receivable at 15.7% of total assets.
Alnylam Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Alnylam Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MAIA Biotechnology Inc.
NYSE MKT:MAIA
|
USA | $35.32 Million |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Catalyst Pharmaceuticals Inc
NASDAQ:CPRX
|
USA | $1.15 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Shanghai Medicilon Inc
SHG:688202
|
China | CN¥2.77 Billion |
|
Absci Corp
NASDAQ:ABSI
|
USA | $195.59 Million |
|
Chengdu Kanghua Biological Products
SHE:300841
|
China | CN¥3.94 Billion |
Alnylam Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.76 | 2.78 | 3.98 |
| Quick Ratio | 2.71 | 2.71 | 3.83 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $2.58 Billion | $2.11 Billion | $1.48 Billion |
Alnylam Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Alnylam Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 55.91 |
| Latest Market Cap to Assets Ratio | 6.38 |
| Asset Growth Rate (YoY) | 17.1% |
| Total Assets | $4.97 Billion |
| Market Capitalization | $31.70 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Alnylam Pharmaceuticals Inc's assets at a significant premium (6.38x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Alnylam Pharmaceuticals Inc's assets grew by 17.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Alnylam Pharmaceuticals Inc (2002–2025)
The table below shows the annual total assets of Alnylam Pharmaceuticals Inc from 2002 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $4.97 Billion | +17.13% |
| 2024-12-31 | $4.24 Billion | +10.71% |
| 2023-12-31 | $3.83 Billion | +7.99% |
| 2022-12-31 | $3.55 Billion | -2.66% |
| 2021-12-31 | $3.64 Billion | +6.93% |
| 2020-12-31 | $3.41 Billion | +42.25% |
| 2019-12-31 | $2.40 Billion | +52.09% |
| 2018-12-31 | $1.57 Billion | -21.05% |
| 2017-12-31 | $1.99 Billion | +57.96% |
| 2016-12-31 | $1.26 Billion | -8.92% |
| 2015-12-31 | $1.39 Billion | +28.43% |
| 2014-12-31 | $1.08 Billion | +156.72% |
| 2013-12-31 | $420.53 Million | +46.26% |
| 2012-12-31 | $287.52 Million | +1.99% |
| 2011-12-31 | $281.92 Million | -28.31% |
| 2010-12-31 | $393.26 Million | -18.31% |
| 2009-12-31 | $481.38 Million | -13.21% |
| 2008-12-31 | $554.68 Million | +12.33% |
| 2007-12-31 | $493.79 Million | +105.74% |
| 2006-12-31 | $240.01 Million | +144.04% |
| 2005-12-31 | $98.35 Million | +48.77% |
| 2004-12-31 | $66.11 Million | +87.89% |
| 2003-12-31 | $35.18 Million | +118.38% |
| 2002-12-31 | $16.11 Million | -- |
About Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute h… Read more